{"disease":{"id":"autoimmune-anemia","name":"autoimmune anemia"},"drugs":{"marketed":[{"drug_id":"prednisone","indication_name":"Acquired (autoimmune) hemolytic anemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone-phosphate","indication_name":"Acquired (autoimmune) hemolytic anemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"sutimlimab","indication_name":"Cold autoimmune hemolytic anemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Enjaymo","generic_name":"SUTIMLIMAB","company_name":"Bioverativ Therapeutics Inc","drug_phase":"marketed","molecular_target":"Complement C1s subcomponent","drug_class":"Classical Complement Pathway Inhibitor [EPC]","quality_score":48,"revenue":null,"mechanism":"Enjaymo works by blocking the activity of the complement C1s subcomponent, a part of the immune system that can mistakenly attack red blood cells."},{"drug_id":"hydrocortisone-succinate","indication_name":"Autoimmune hemolytic anemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Solu-Cortef","generic_name":"hydrocortisone succinate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone-acetate","indication_name":"Autoimmune hemolytic anemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortifoam","generic_name":"HYDROCORTISONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Autoimmune hemolytic anemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"sutimlimab-jome","indication_name":"Cold autoimmune hemolytic anemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ENJAYMO","generic_name":"SUTIMLIMAB-JOME","company_name":"RECORDATI RARE DISEASES, INC.","drug_phase":"marketed","molecular_target":"Complement C1s subcomponent","drug_class":"Classical Complement Pathway Inhibitor [EPC]","quality_score":34,"revenue":null,"mechanism":""},{"drug_id":"betamethasone-acetate","indication_name":"Autoimmune hemolytic anemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Celestone Soluspan","generic_name":"BETAMETHASONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Autoimmune hemolytic anemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"prednison","indication_name":"Autoimmune hemolytic anemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednison","company_name":"Wen Zhang","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolone","indication_name":"Autoimmune hemolytic anemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"hydrocortisone","indication_name":"Autoimmune hemolytic anemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Autoimmune hemolytic anemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"prednisone","indication_name":"Autoimmune hemolytic anemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"betamethasone","indication_name":"Autoimmune hemolytic anemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"cortisol","indication_name":"Autoimmune hemolytic anemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolone","indication_name":"Autoimmune hemolytic anemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisolon","indication_name":"Autoimmune hemolytic anemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Autoimmune hemolytic anemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":19,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07019038","title":"National Longitudinal Cohort of Hematological Diseases- Autoimmune Hemolytic Anemia","phase":"","overall_status":"RECRUITING","enrollment_count":9999,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT05937828","title":"OBS'CEREVANCE: French Cohort of Pediatric Autoimmune Cytopenia","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT04645199","title":"National Longitudinal Cohort of Hematological Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":2300,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT04024202","title":"Data Registry of Auto Immune Hemolytic Anemia","phase":"","overall_status":"UNKNOWN","enrollment_count":720,"lead_sponsor_name":"Sanquin Research & Blood Bank Divisions","has_results":false},{"nct_id":"NCT04057703","title":"Balance Benefit / Risk of Immunomodulatory Treatments at the Child and Adolescent for Autoimmune Cytopenia.","phase":"","overall_status":"COMPLETED","enrollment_count":454,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT05238181","title":"Pyloric or Pseudopyloric Metaplasia of the Corpus Mucosa in Autoimmune Gastritis","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"National Cheng-Kung University Hospital","has_results":false},{"nct_id":"NCT07518277","title":"A Multicenter, Prospective, Randomized Controlled Study Comparing Glucocorticoid Combined With Sirolimus With Monotherapy of Glucocorticoid in the Treatment of Newly Diagnosed Mild Autoimmune Hemolytic Anemia","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":216,"lead_sponsor_name":"Chen Miao","has_results":false},{"nct_id":"NCT07175493","title":"A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":158,"lead_sponsor_name":"Keymed Biosciences Co.Ltd","has_results":false},{"nct_id":"NCT03269292","title":"Clinical Characteristics and Treatment Outcomes of Patients With Autoimmune Hemolytic Anemia","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT05786573","title":"A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":134,"lead_sponsor_name":"Zenas BioPharma (USA), LLC","has_results":false},{"nct_id":"NCT05098600","title":"The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic","phase":"","overall_status":"COMPLETED","enrollment_count":123,"lead_sponsor_name":"Faculty Hospital Kralovske Vinohrady","has_results":false},{"nct_id":"NCT02502903","title":"Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":122,"lead_sponsor_name":"Bioverativ, a Sanofi company","has_results":false},{"nct_id":"NCT04119050","title":"Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":118,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT03941184","title":"Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity","phase":"","overall_status":"COMPLETED","enrollment_count":114,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05648968","title":"A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":90,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03764618","title":"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Rigel Pharmaceuticals","has_results":true},{"nct_id":"NCT03576742","title":"Severe Immune Cytopenia Registry Www.Sic-reg.Org","phase":"","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Medical University of Graz","has_results":false},{"nct_id":"NCT03918265","title":"Tacrolimus Treatment for Refractory Autoimmune Cytopenia","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT05263817","title":"A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":75,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT07039422","title":"Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04324411","title":"Sirolimus Combined With ATRA for the Treatment of Auto-Immune Anemia","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT07453368","title":"Orelabrutinib in the Treatment of Relapsed/Refractory AIHA","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT03827603","title":"Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Eugene Nikitin","has_results":false},{"nct_id":"NCT04814394","title":"The Significance of Release of T-follicular Helper and T-follicular Regulatory Cells in Autoimmune Haemolytic Anemia Before and After Tratment","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT05711264","title":"Presence of Circulating Cluster of Differentiation 4 Positive 28 Null T Helper Lymphocytes(CD4+CD28-) in Patients With Autoimmune Hemolytic Anemia.","phase":"","overall_status":"UNKNOWN","enrollment_count":46,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT06021977","title":"The Safety and Efficacy of Zanubrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":33,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT04083014","title":"Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT01181154","title":"Rituximab in Auto-Immune Hemolytic Anemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05057481","title":"Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT05057468","title":"Second-line Treatment of Primary Autoimmune Hemolytic Anemia","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT00001630","title":"Treatment of Autoimmune Thrombocytopenia (AITP)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT07205315","title":"A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"Grit Biotechnology","has_results":false},{"nct_id":"NCT07441525","title":"UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":27,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT02158195","title":"Immunopathology of Autoimmune Hemolytic Anemia","phase":"","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Centre Hospitalier Universitaire Dijon","has_results":false},{"nct_id":"NCT03538041","title":"A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT02828670","title":"Role of T Follicular Helper Cells in Autoimmune Hemolytic Anemia (TFH in AIHA)","phase":"","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Centre Hospitalier Universitaire Dijon","has_results":false},{"nct_id":"NCT07324889","title":"An Open-label, Single-arm, Prospective, Multicenter, Phase I/II Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-T Cell Therapy for Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":24,"lead_sponsor_name":"Yihao Wang","has_results":false},{"nct_id":"NCT03226678","title":"Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Apellis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT07149818","title":"A Single-arm Phase 2 Prospective Clinical Study of Linprixel in the Treatment of Relapsed/Refractory Autoimmune Hemolytic Anemia","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":22,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT05002777","title":"Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":22,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06847607","title":"A Multicenter Prospective Study of Iptacopan in the Treatment of Refractory/Relapsed Autoimmune Hemolytic Anemia (AIHA)","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Bing Han","has_results":false},{"nct_id":"NCT06921980","title":"Brain Function and Psychological Changes Related to Cell Therapy for Autoimmune Hemolytic Anemia","phase":"","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT04398459","title":"The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":18,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT06888960","title":"Safety Study of CC312 in Autoimmune Disease Patients","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"CytoCares Inc","has_results":false},{"nct_id":"NCT06733610","title":"CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT07453836","title":"Research on YTS109 Cell in Patients With Recurrent/Refractory Autoimmune Hemolytic Anemia","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":13,"lead_sponsor_name":"China Immunotech (Beijing) Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT06212154","title":"CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":13,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT05073458","title":"Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT07287930","title":"A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":13,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT07091370","title":"Inaticabtagene Autoleucel Injection in the Treatment of Autoimmune Hemolytic Anemia After Three or More Lines of Therapy","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":12,"lead_sponsor_name":"Juventas Cell Therapy Ltd.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}